Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor

Journal of Physiology

Volumn 589, Issue 4, 2011, Pages 939-951

  Flores Munoz M ^a   Smith, N J ^b   Haggerty, C ^a   Milligan, G ^b   Nicklin, S A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1-9; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; ATRIAL NATRIURETIC FACTOR; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; ICATIBANT; LOSARTAN; MAS RECEPTOR; MYOSIN HEAVY CHAIN BETA; MYOSIN LIGHT CHAIN; RECEPTOR; UNCLASSIFIED DRUG; VASOPRESSIN;

ANIMAL CELL; ARTICLE; BINDING ASSAY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CELL SIZE; DRUG TARGETING; ENDOTHELIUM; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART MUSCLE CELL; MARKER GENE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOASSAY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; CELL LINE, TRANSFORMED; CELL SURVIVAL; CELLS, CULTURED; HELA CELLS; HUMANS; HYPERTROPHY; MYOCYTES, CARDIAC; PEPTIDE FRAGMENTS; RABBITS; RATS; RECEPTOR, ANGIOTENSIN, TYPE 2; SIGNAL TRANSDUCTION;

EID: 79951711793     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2010.203075     Document Type: Article

References (53)

1. Abadir PM, Periasamy A, Carey RM & Siragy HM (2006). Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 48, 316-322.
2. q/11, phospholipase Cβ3 and extracellular signal-regulated kinase 1/2 via angiotensin II type 1 receptor. Chin Med J (Engl) 117, 88-93.
3. Bartunek J, Weinberg EO, Tajima M, Rohrbach S & Lorell BH (1999). Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation 99, 22-25.
4. Brilla CG, Scheer C & Rupp H (1997). Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J Hypertens Suppl 15, S13-19.
5. Bunkenburg B, van Amelsvoort T, Rogg H & Wood JM (1992). Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 20, 746-754.
6. Campbell DJ, Kladis A & Duncan AM (1993). Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 22, 513-522.
7. Cigola E, Kajstura J, Li B, Meggs LG & Anversa P (1997). Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res 231, 363-371.
8. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y & Penninger JM (2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828.
9. D'Amore A, Black MJ & Thomas WG (2005). The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 46, 1347-1354.
10. De Mello WC (2009). Opposite effects of angiotensin II and angiotensin (1-7) on impulse propagation, excitability and cardiac arrhythmias. Is the overexpression of ACE2 arrhythmogenic? Regul Pept 153, 7-10.
11. De Mello WC, Ferrario CM & Jessup JA (2007). Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Syst 8, 74-80.
12. Dias-Peixoto MF, Santos RA, Gomes ER, Alves MN, Almeida PW, Greco L, Rosa M, Fauler B, Bader M, Alenina N & Guatimosim S (2008). Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension 52, 542-548.
13. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE & Acton S (2000). A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87, E1-9.
14. Ferreira AJ, Santos RA & Almeida AP (2002). Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts. Braz J Med Biol Res 35, 1083-1090.
15. Galandrin S, Oligny-Longpre G & Bouvier M (2007). The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28, 423-430.
16. Garabelli PJ, Modrall JG, Penninger JM, Ferrario CM & Chappell MC (2008). Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp Physiol 93, 613-621.
17. Goldenberg I, Grossman E, Jacobson KA, Shneyvays V & Shainberg A (2001). Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors. J Hypertens 19, 1681-1689.
18. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK & Katovich MJ (2007). Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292, H736-742.
19. Grobe JL, Mecca AP, Mao H & Katovich MJ (2006). Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 290, H2417-2423.
20. Hwang GS, Oh KS, Koo HN, Seo HW, You KH & Lee BH (2006). Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure. Eur J Pharmacol 540, 131-138.
21. Igarashi M, Hirata A, Nozaki H, Kadomoto-Antsuki Y & Tominaga M (2007). Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats. Diabetes Res Clin Pract 75, 267-277.
22. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM & Erdos EG (2002). Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension 39, 976-981.
23. Kenakin T (2007). Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72, 1393-1401.
24. Kenakin T (2008). What systems can and can't do. Br J Pharmacol 153, 841-843.
25. Kokkonen JO, Saarinen J & Kovanen PT (1997). Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 95, 1455-1463.
26. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y, Iba O, Amano K & Matsubara H (2003). Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 41, 99-107.
27. Laskowski A, Woodman OL, Cao AH, Drummond GR, Marshall T, Kaye DM & Ritchie RH (2006). Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72, 112-123.
28. Majalahti T, Suo-Palosaari M, Sarman B, Hautala N, Pikkarainen S, Tokola H, Vuolteenaho O, Wang J, Paradis P, Nemer M & Ruskoaho H (2007). Cardiac BNP gene activation by angiotensin II in vivo. Mol Cell Endocrinol 273, 59-67.
29. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RA, Walther T, Touyz RM & Reudelhuber TL (2008). Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103, 1319-1326.
30. Metcalfe BL, Huentelman MJ, Parilak LD, Taylor DG, Katovich MJ, Knot HJ, Sumners C & Raizada MK (2004). Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer. Hypertension 43, 1233-1238.
31. Miura S & Karnik SS (1999). Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J Hypertens 17, 397-404.
32. Nakagami H, Takemoto M & Liao JK (2003). NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 35, 851-859.
33. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, Roman M, Ramirez C, Copaja M, Diaz-Araya G, Castro P & Lavandero S (2006). Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48, 572-578.
34. Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U, Apablaza F, Gonzalez L, Hernandez C, Varas M, Lopez R, Godoy I, Verdejo H & Chiong M (2010). Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 28, 1054-1064.
35. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T & Inada M (1997). Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96, 3954-3962.
36. Pan J, Singh US, Takahashi T, Oka Y, Palm-Leis A, Herbelin BS & Baker KM (2005). PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and mitogen-activated protein kinases in cardiomyocytes. J Cell Physiol 202, 536-553.
37. Peiro C, Vallejo S, Gembardt F, Azcutia V, Heringer-Walther S, Rodriguez-Manas L, Schultheiss HP, Sanchez-Ferrer CF & Walther T (2007). Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. J Hypertens 25, 2421-2425.
38. Pinheiro SV, Ferreira AJ, Kitten GT, da Silveira KD, da Silva DA, Santos SH, Gava E, Castro CH, Magalhaes JA, da Mota RK, Botelho-Santos GA, Bader M, Alenina N, Santos RA & Simoes e Silva AC (2009). Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75, 1184-1193.
39. Ritter O, Schuh K, Brede M, Rothlein N, Burkard N, Hein L & Neyses L (2003). AT2 receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway. FASEB J 17, 283-285.
40. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL & Touyz RM (2007). Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49, 185-192.
41. Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT & Ferreira AJ (2006). Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 47, 996-1002.
42. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R & Walther T (2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100, 8258-8263.
43. Schluter KD & Wenzel S (2008). Angiotensin II: a hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks. Pharmacol Ther 119, 311-325.
44. Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA & Lemos VS (2007). Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 28, 702-707.
45. Smith NJ, Bennett KA & Milligan G (2010). When simple agonism is not enough: Emerging modalities of GPCR ligands. Mol Cell Endocrinol (in press).
46. Soares de Moura R, Resende AC, Emiliano AF, Tano T, Mendes-Ribeiro AC, Correia ML & de Carvalho LC (2004). The role of bradykinin, AT2 and angiotensin 1-7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat. Br J Pharmacol 141, 860-866.
47. Swaney JS, Roth DM, Olson ER, Naugle JE, Meszaros JG & Insel PA (2005). Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc Natl Acad Sci U S A 102, 437-442.
48. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H & Hannan RD (2002). Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90, 135-142.
49. Vijayan K, Szotek EL, Martin JL & Samarel AM (2004). Protein kinase C-α-induced hypertrophy of neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 287, H2777-2789.
50. Walters PE, Gaspari TA & Widdop RE (2005). Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45, 960-966.
51. Wang C, Jayadev S & Escobedo JA (1995). Identification of a domain in the angiotensin II type 1 receptor determining Gq coupling by the use of receptor chimeras. J Biol Chem 270, 16677-16682.
52. Yayama K & Okamoto H (2008). Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 8, 312-318.
53. Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I, Hiroi Y, Mizuno T & Yazaki Y (1996). Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem 271, 33592-33597.